{"disease":{"id":"hemophilia-a-with-inhibitor","name":"hemophilia a with inhibitor"},"drugs":{"marketed":[{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"hympavzi","indication_name":"Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia B (congenital factor IX deficiency) without factor IX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hympavzi","generic_name":"Marstacimab-Hncq","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)","drug_class":"Tissue Factor Pathway Inhibitor (TFPI) Antagonist","quality_score":65,"revenue":null,"mechanism":"Monoclonal antibody against TFPI Kunitz domain 2 to neutralize TFPI and enhance coagulation."},{"drug_id":"gbt021601","indication_name":"Treatment of adult patients with severe hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gbt021601","generic_name":"gbt021601","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pf-07202954-single-dose","indication_name":"Hemophilia A with inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07202954 Single Dose","generic_name":"pf-07202954-single-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"concizumab","indication_name":"hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."},{"drug_id":"concizumab","indication_name":"hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alhemo","generic_name":"CONCIZUMAB","company_name":"Novo Nordisk Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Tissue Factor Pathway Inhibitor Antagonist [EPC]","quality_score":52,"revenue":null,"mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03619863","title":"ATHN 7: Hemophilia Natural History Study","phase":"","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT03818529","title":"ATHN 8: Previously Untreated Patients (PUPs) Matter Study","phase":"","overall_status":"COMPLETED","enrollment_count":237,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT06569108","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Suzhou Alphamab Co., Ltd.","has_results":false},{"nct_id":"NCT06864975","title":"Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Runhui WU","has_results":false},{"nct_id":"NCT07096349","title":"Multidimensional Assessment of Chronic Pain in Severe Haemophilia A","phase":"","overall_status":"RECRUITING","enrollment_count":109,"lead_sponsor_name":"Investigación en Hemofilia y Fisioterapia","has_results":false},{"nct_id":"NCT03598725","title":"Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":55,"lead_sponsor_name":"Beijing Children's Hospital","has_results":false},{"nct_id":"NCT04647227","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"American Thrombosis and Hemostasis Network","has_results":false},{"nct_id":"NCT06312475","title":"Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"Suzhou Alphamab Co., Ltd.","has_results":false},{"nct_id":"NCT00851721","title":"Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05888870","title":"ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Institute of Hematology & Blood Diseases Hospital, China","has_results":false},{"nct_id":"NCT03935334","title":"Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"AryoGen Pharmed Co.","has_results":false},{"nct_id":"NCT02764489","title":"FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05981274","title":"A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","phase":"","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tri-Service General Hospital","has_results":false},{"nct_id":"NCT03951103","title":"rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A","phase":"","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Swedish Orphan Biovitrum","has_results":false},{"nct_id":"NCT04181697","title":"HemFitBit, an Observational Study of Physical Activity in People With Moderate and Severe Haemophilia A","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT02919800","title":"A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"OPKO Health, Inc.","has_results":false},{"nct_id":"NCT04723693","title":"An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Haemnet","has_results":true},{"nct_id":"NCT05651061","title":"A Phase I of SS109 in Hemophilia A or and B With Inhibitors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT02484638","title":"Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":25,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT02448680","title":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Laboratoire français de Fractionnement et de Biotechnologies","has_results":true},{"nct_id":"NCT04768699","title":"Study of Recombinant Human Coagulation Factor VIIa for Injection (FⅦa) in Patients With Hemophilia.","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","has_results":false},{"nct_id":"NCT06010953","title":"SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Jiangsu Gensciences lnc.","has_results":false},{"nct_id":"NCT04592692","title":"A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Ascension Healthcare Development Limited","has_results":false},{"nct_id":"NCT04548791","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"Catalyst Biosciences","has_results":false},{"nct_id":"NCT04489537","title":"Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Catalyst Biosciences","has_results":false},{"nct_id":"NCT03093480","title":"A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Bioverativ, a Sanofi company","has_results":true},{"nct_id":"NCT06568302","title":"The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"ApcinteX Ltd","has_results":false},{"nct_id":"NCT07158606","title":"Understanding Treatment Outcomes and Immunologic Mechanisms in Altuviiio Immune Tolerance Induction","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Versiti Blood Health","has_results":false},{"nct_id":"NCT06155955","title":"Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT05281185","title":"Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Chulalongkorn University","has_results":false},{"nct_id":"NCT04789954","title":"Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"AryoGen Pharmed Co.","has_results":false},{"nct_id":"NCT03407651","title":"Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Catalyst Biosciences","has_results":true},{"nct_id":"NCT04072237","title":"Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Catalyst Biosciences","has_results":true},{"nct_id":"NCT06357572","title":"Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem","phase":"","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Enzyre B.V.","has_results":false},{"nct_id":"NCT04303572","title":"The Hemophilia Inhibitor Eradication Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Margaret Ragni","has_results":true},{"nct_id":"NCT03204539","title":"INdividualized ITI Based on Fviii(ATE) Protection by VWF","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University of California, Davis","has_results":true},{"nct_id":"NCT04303559","title":"The Hemophilia Inhibitor Prevention Trial","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Margaret Ragni","has_results":true}],"total":37},"guidelines":[],"source":"Drug Landscape verified database"}